- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03324607
Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI (COPD)
Effects of Glycopyrrolate/Formoterol (Bevespi) on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will characterize ventilation and gas transfer distributions in GOLD II and III COPD patients and assess the potential for these physiological parameters as a novel phenotyping method using Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas.
The study will additionally quantify regional ventilation and gas transfer response to glycopyrrolate/formoterol in GOLD II and III COPD patients.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke Asthma, Allergy, and Airway Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of COPD confirmed by post-bronchodilator spirometry demonstrating (forced expiratory volume at 1 second(FEV1)/forced vital capacity (FVC) < 0.70 and forced expiratory volume at 1 second (FEV1) in GOLD 2 or 3 stage (30%≤ (forced expiratory volume at 1 second [FEV1] < 80%)
- Willing and able to give informed consent and adhere to visit/protocol schedules
- Women of childbearing potential must have a negative urine pregnancy test
Exclusion Criteria:
- Upper respiratory tract infection within 6 weeks
Chronic systemic corticosteroid use > 10 mg/day of prednisone
- Chronic oxygen use (intermittent or continuous)
- Previous lung resection surgery or decortication
- Previous history of pneumothorax
- Evidence of interstitial, occupational or chronic infectious lung disease by imaging studies
- History of exposure to occupational or environmental hazards that are known to cause lung diseases
- For women of child bearing potential, positive pregnancy test
- Major chronic illnesses which in the judgement of the study physician would interfere with participation in the study
Patients who are not willing to withhold COPD inhalers for the run-in period.
- MRI is contraindicated based on responses to MRI screening questionnaire
- Subject is pregnant or lactating
- Respiratory illness of a bacterial or viral etiology within 30 days of MRI
- Subject has any form of known cardiac arrhythmia
- Subject does not fit into 129Xe vest coil used for MRI
- Subject cannot hold his/her breath for 15 seconds
- Subject deemed unlikely to be able to comply with instructions during imaging
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm
glycopyrrolate/formoterol (Bevespi) 2 puffs twice a day taken for two weeks, started after completion of the study XeMRI.
A follow up xeMRI occurs at the end of the two weeks of taking the Bevespi in a Pre-post study design.
|
There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
Other Names:
There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventilation Distribution as Measured by Ventilation Defect+Low Percent
Time Frame: Week 2
|
The ventilation distribution as measured by ventilation defect+low percent is to measure the area of the lung that has no air.
|
Week 2
|
Barrier Uptake.
Time Frame: 2 weeks
|
Diffusion of Xe gas across the lung membrane into the blood.
This measures how well oxygen goes through the lung into the blood.
|
2 weeks
|
Red Blood Cell (RBC) Uptake
Time Frame: 2 weeks
|
Amount of Xe gas that enters the blood stream after it diffuses across the lung membrane
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulmonary Function Test - Forced Vital Capacity (FVC)
Time Frame: 2 weeks
|
Forced vital capacity (FVC) is the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible, as measured by spirometry.
|
2 weeks
|
Pulmonary Function Test - Forced Expiratory Volume-one Second (FEV1)
Time Frame: 2 weeks
|
FEV1 is a lung airflow measure to assess the amount of air that can be blown out in one second.
|
2 weeks
|
Pulmonary Function Test - Total Lung Capacity (TLC)
Time Frame: 2 weeks
|
Total Lung Capacity (TLC) is the volume in the lungs at a maximal inhalation.
|
2 weeks
|
Pulmonary Function Test - Residual Volume (RV)
Time Frame: 2 weeks
|
Residual volume (RV) is the volume of air remaining in the lungs after a maximal exhalation.
|
2 weeks
|
Pulmonary Function Test - Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)
Time Frame: 2 weeks
|
DLCO measures the ability of oxygen to travel from the air sacs of the lungs to the blood stream.
|
2 weeks
|
6-minute Walk Test (6MWT)
Time Frame: 2 weeks
|
The 6-minute walk test (6MWT) measures the distance walked at a natural pace for 6 minutes.
|
2 weeks
|
St. George's Respiratory Questionnaire (SGRQ) Score
Time Frame: 2 weeks
|
The SGRQ is used to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease.
Scores range from 0 to 100, with higher scores indicating more limitations.
|
2 weeks
|
Rating of Perceived Dyspnea (RPD) Scale
Time Frame: 2 weeks
|
A patient reported outcome to measure perceived exertion during physical activity.
The RPD scale goes from 0 to 10, where 0 = no shortness of breath at all and 10 = maximal shortness of breath (needing to stop the exercise or activity).
|
2 weeks
|
COPD Assessment Test (CAT) Score
Time Frame: 2 weeks
|
Functional measurement for COPD patients.
Range of CAT scores from 0-40.
Higher scores denote a more severe impact of COPD on a patient's life.
|
2 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yuh Chin Huang, MD, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00086693
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
University Medical Center GroningenCompleted
-
Istituto Nazionale di Ricovero e Cura per AnzianiRecruiting
-
Bio-Sensing Solutions S.L. (DyCare)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Centre...Not yet recruiting
-
Sir Run Run Shaw HospitalRecruiting
-
University Hospital, BrestRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)Recruiting
-
Baylor Research InstituteNot yet recruiting
-
Polytechnic Institute of PortoNippon Gases PortugalRecruiting
Clinical Trials on hyperpolarized 129Xe gas MRI
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)TerminatedChronic Obstructive Pulmonary DiseaseUnited States
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Ontario Lung Association; Cyclomedica Australia...Enrolling by invitation
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI)CompletedRadiation InjuryUnited States
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI); University of Wisconsin,...CompletedIdiopathic Pulmonary FibrosisUnited States
-
Bastiaan DriehuysNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; Children... and other collaboratorsRecruitingInterstitial Lung DiseasesUnited States
-
McMaster UniversitySt. Joseph's Healthcare HamiltonRecruitingBronchiectasis | Chronic Obstructive Pulmonary Disease | Asthma | Emphysema | Pulmonary Fibrosis | Alpha 1-Antitrypsin Deficiency | Bronchopulmonary Dysplasia | Sarcoidosis, PulmonaryCanada
-
Xemed LLCChildren's Hospital of PhiladelphiaNot yet recruiting
-
Bastiaan DriehuysRecruitingPulmonary Arterial Hypertension | Interstitial Lung Disease | COPDUnited States
-
Eric A. HoffmanCompleted